PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number	-	10599377		
	Filing Date				
INFORMATION DISCLOSURE	First Named Inventor	Ulf La	arsson		
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit				
(Not for Submission under 57 of K 1.55)	Examiner Name				
	Attorney Docket Numb	er	ASZN0125-100 101420-1P US		

					U.S.F	PATENTS	Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	ate	Name of Pate of cited Docu	Pages,Columns,Lines wher Relevant Passages or Rele Figures Appear				
VY	1	6096924		2000-08	-01	Studer et al.					
If you wisl	h to ac	l dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	<u> </u>	Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	ICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Kind Publicat Code <sup>1</sup> Date		Name of Pate of cited Docu	Releva		Lines where ges or Relev		
	1										
If you wis	h to a	ı dd additional U.S. Publi	shed Ap	plication	citation	information p	lease click the Ad	l d buttor	Add		
		and result in				ENT DOCUM			Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	T5
W	1	0508687	EP			1992-10-14	Fisons PLC				
M	2	01/92263	wo			2001-12-06	AstraZeneca AB				
M	3	00/34283	wo			2000-06-15	AstraZeneca AB	-			

,								·····				
			Application Number Filing Date				10599377					
												STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)
Art Unit												
Examiner Name												
				Attorney Docket Number			er	ASZN0125-100 101420-1P US				
				1.	• •							
			T			<del></del>	1				$\overline{}$	
M	4	99/05143	wo	1999-02-		999-02-0	M2 I'	Astra Pharmaceuticals Ltd., et al.				
If you wis	h to a	<u>l</u> dd additional Foreign P	atent Do	cument	citation ir	nformatio	on ple	ase click the Add buttor	Add	1		
								UMENTS	Remove			
	<u> </u>	Include name of the								<u>,                                    </u>	т—	
Examiner Initials*	xaminer itials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), title of the (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5		
				•		•						
	1											
ı												
If you wis	h to a	dd additional non-pater	nt literatu	re docu	ment citat	tion infor	matio	on please click the Add t	outton A	dd	_1	
				EX	CAMINER	SIGNA	TURE					
Examiner Signature V Balasussamoun Date Considered 9/287							7/28/1	07				
		nitial if reference consid	lered, wh	ether o	r not citati	ion is in d		rmance with MPEP 609 ith next communication				

<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 
<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.